← SynDRA
CONIVAPTAN
SynDRA canonical compound SYN0020299 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | AVPR2 |
|---|
| Mechanism of action | Vasopressin receptor antagonist |
|---|
| Indication | hyponatremia |
|---|
| Disease area | endocrinology |
|---|
All known targets
- AVPR1A
- AVPR2
- Avpr1a
- Avpr2
- OXT
- OXTR
- Oxtr
Mechanisms of action (all sources)
- Vasopressin receptor antagonist
- AVPR2 ANTAGONIST
- Vasopressin V2 receptor antagonist
- AVPR1A ANTAGONIST
- Vasopressin V1a receptor antagonist
- AVPR2 MODULATOR
- AVPR1A MODULATOR
Drug classes
- Vasopressin Receptor Antagonists
- Antidiuretic Hormone Receptor Antagonists
- Natriuretic Agents
- Vasopressin Receptor Antagonist
- Cytochrome P450 3A Inhibitors
ATC classes
Cross-references
Synonyms
- conivaptan hydrochloride
- vaprisol
- YM-087
- conivaptan HCl
- Conivaptan [INN]
- YM087
- Conivaptan (INN)
- Vaprisol (TN)
- N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide
- N-{4-[(2-methyl-4,5-dihydroimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl}biphenyl-2-carboxamide
- 4'-((4,5-dihydro-2-methylimidazo(4,5-d)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
- YM 087
- 0NJ98Y462X
- CHEBI:681850
- conivaptanum
- RefChem:56750
- DTXCID3097711
- C03XA02
- C32H26N4O2
- A1ECE
- CONIVAPTAN [MI]
- CONIVAPTAN [VANDF]
- CONIVAPTAN [WHO-DD]
- SCHEMBL49815
- UNII-0NJ98Y462X
- GTPL2203
- SCHEMBL4625101
- SCHEMBL29406590
- BDBM85095
- IKENVDNFQMCRTR-UHFFFAOYSA-N
- HMS3745C21
- EBC-27237
- EX-A10860
- PDSP1_001735
- PDSP2_001718
- AKOS015917893
- AKOS027326517
- CAS_151171
Look up CONIVAPTAN in the interactive SynDRA portal →